Cargando…
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve t...
Ejemplares similares
-
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020) -
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013) -
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
por: Pizzuti, Laura, et al.
Publicado: (2019) -
PANHER study: a 20-year treatment outcome analysis from a multicentre
observational study of HER2-positive advanced breast cancer patients from the
real-world setting
por: Pizzuti, Laura, et al.
Publicado: (2021) -
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)